BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-23

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

NCT02880618

Heart Failure

UNKNOWN

Impact of Barostimulation on Hemodynamics in Adults With Heart Failure

NCT07335510

HFrEF - Heart Failure With Reduced Ejection Fraction

NOT_YET_RECRUITING NA

Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

NCT05860348

Heart Failure

TERMINATED

Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

NCT00751972

Chronic Heart Failure

COMPLETED NA

Reprieve System Pilot Study

NCT06272734

Acute Decompensated Heart Failure

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Summary:

The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry will be performed with subjects who have been recently implanted with the BAROSTIM NEO System in accordance with CE-Mark approved criteria for resistant hypertension and have evidence of HFpEF per the registry enrollment criteria. Subjects must be enrolled within 30 days from implant but prior to therapy activation. Up to 70 subjects will be enrolled at up to 10 sites. Data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3 and 6 months after the device was implanted, at which time each subject will be exited from the registry.

Eligibility Criteria:

The CE-Mark approved indications and contraindications for the BAROSTIM NEO system in the treatment of resistant hypertension include:

* Indications

* Systolic blood pressure greater than or equal to 140 mmHg, and
* Resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications
* Contraindications

* Bilateral carotid bifurcations located above the level of the mandible
* Baroreflex failure or autonomic neuropathy
* Uncontrolled, symptomatic cardiac bradyarrhythmias
* Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50%
* Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAROSTIM NEO™ System

Implantation of the BAROSTIM NEO™ System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sign an Ethics Committee (EC) approved informed consent form for the registry.
* Implanted with the BAROSTIM NEO system in accordance with CE-Mark approved indications and contraindications for resistant hypertension within 30 days prior to enrollment.
* BAROSTIM THERAPY not yet chronically activated.
* Pre-implant echocardiogram with left ventricular ejection fraction ≥ 50% within 30 days prior to implant.
* On stable, maximally-tolerated, guideline-directed cardiovascular medications for at least 30 days prior to enrollment.
* Objective evidence of heart failure according to the following criteria:

* Hospitalization for heart failure within 12 months prior to enrollment OR
* Echocardiographic evidence of diastolic dysfunction (LA Volume Index \>34 ml/m2 OR E/e \>13) within 30 days prior to enrollment OR
* NTproBNP \> 220 pg/mL or BNP \> 80 pg/mL (in atrial fibrillation, NTproBNP \> 600 pg/mL or BNP \> 200 pg/mL) within 30 days prior to enrollment

Exclusion Criteria

* Heart failure secondary to a reversible or treatable condition such as, cardiac structural valvular disease, acute myocarditis and pericardial constriction.
* Heart failure secondary to right ventricular failure or right ventricular myocardial infarction.

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Burkert Pieske, PhD

Role: STUDY_CHAIR

Universitätmedizin Berlin - Charité

Locations

Explore where the study is taking place and check the recruitment status at each participating site.